First trimester screening and progesterone levels in HIV positive women under HAART therapy

HIV (Human Immunodeficiency Virus) that ultimately determines the development of AIDS evolved in time in a pandemic disease. Our study evaluated first trimester markers for aneuploidy, serum progesterone levels in first and second trimester in HIV positive pregnant women under HAART therapy.

It was a prospective study that took place between January 2017- December 2019 in "Cuza-Vodă" Hospital from Romania. We analysed first trimester PAPP-A, βHCG, first and second trimester progesterone of 25 HIV positive pregnant women under HAART therapy and compared them with seronegative pregnant women.

Both βHCG and first and second trimester progesterone were lower in HIV positive women under HAART therapy.

These alterations of first trimester markers for aneuploidy might lead to an over estimation of the risk for Down syndrome.

Obstetricians need to know the alterations of first trimester markers for aneuploidy so they can correctly advise these women accordingly.